M

Mayinglong Pharmaceutical Group Co Ltd
SSE:600993

Watchlist Manager
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Watchlist
Price: 26.21 CNY -0.46% Market Closed
Market Cap: 11.3B CNY
Have any thoughts about
Mayinglong Pharmaceutical Group Co Ltd?
Write Note
Mayinglong Pharmaceutical Group Co Ltd
/
Income Statement
/
Income from Continuing Operations

Mayinglong Pharmaceutical Group Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mayinglong Pharmaceutical Group Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
M
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Income from Continuing Operations
¥493.6m
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
10%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Income from Continuing Operations
¥3.3B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Income from Continuing Operations
¥3.1B
CAGR 3-Years
9%
CAGR 5-Years
18%
CAGR 10-Years
24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Income from Continuing Operations
¥5.4B
CAGR 3-Years
-5%
CAGR 5-Years
2%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Income from Continuing Operations
¥4.3B
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
6%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Income from Continuing Operations
-¥780.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mayinglong Pharmaceutical Group Co Ltd
Glance View

Market Cap
11.3B CNY
Industry
Pharmaceuticals

In the corridors of China's pharmaceutical industry, Mayinglong Pharmaceutical Group Co Ltd stands out with its roots deeply embedded in history while its branches stretch ambitiously into the future. Founded in 1582 during the Ming Dynasty, this firm has garnered a reputation for its innovative approach to traditional Chinese medicine. The company's evolution from an apothecary serving local communities to a publicly traded enterprise mirrors the dynamic growth of China itself. As the world became increasingly captivated by holistic health solutions, Mayinglong capitalized on its heritage of time-tested remedies, turning ancient formulations into modern products. Their flagship product, Mayinglong Hemorrhoid Ointment, is a renowned success, both domestically and internationally, symbolizing the company's unique ability to blend ancient wisdom with contemporary health needs. Mayinglong's business model thrives on a well-balanced portfolio that includes not only traditional Chinese medicines but also a growing pipeline of innovative pharmaceuticals and healthcare products. Leveraging state-of-the-art technology in their R&D centers, they develop new drugs and therapies that align with both modern health trends and the regulatory demands of global markets. The group's revenue streams are diversified across multiple segments, including over-the-counter products, prescription medications, and personal care items. With a vast distribution network both in China and abroad, Mayinglong benefits from scale and brand recognition. Their strategy is a testament to the harmonious merger of tradition and modernity, driving profitability through a deep understanding of consumer needs paired with scientific innovation.

Intrinsic Value
31.89 CNY
Undervaluation 18%
Intrinsic Value
Price
M
What is Intrinsic Value?

See Also

What is Mayinglong Pharmaceutical Group Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
493.6m CNY

Based on the financial report for Sep 30, 2024, Mayinglong Pharmaceutical Group Co Ltd's Income from Continuing Operations amounts to 493.6m CNY.

What is Mayinglong Pharmaceutical Group Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
10%

Over the last year, the Income from Continuing Operations growth was 0%. The average annual Income from Continuing Operations growth rates for Mayinglong Pharmaceutical Group Co Ltd have been 1% over the past three years , 8% over the past five years , and 10% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.